Navigation Links
Replidyne Announces Positive Phase I Results for Topical Antibiotic,REP8839

to cause long-term sensitization and irritancy. No sensitization reactions were recorded in any of the subjects, and low irritancy potential was confirmed. Additionally, in all Phase I studies no serious adverse events were observed in any study subject.

About REP8839

REP8839 is a novel topical antibacterial ointment that targets the bacterial methionyl tRNA (MetRS) enzyme. MetRS is an unexploited target in clinically-important Gram-positive bacteria and represents a promising platform for the development of new antibacterial agents with no cross-resistance to currently marketed antibiotics. In vitro, REP8839 is highly active against major skin pathogens such as Streptococcus pyogenes and Staphylococcus aureus (S. aureus), including drug-resistant strains such as MRSA, mupirocin-resistant and vancomycin-resistant S. aureus.

About Impetigo

Impetigo is a contagious skin disorder caused by bacterial infection and characterized by crusting, red skin lesions, most frequently affecting children. It is the third most common skin disease in children, causing peak incidence among those aged two to five years. Since 2004, the incidence of impetigo has increased 21 percent. In 2006, topical antibiotic prescriptions accounted for 48 percent of all impetigo treatments.

About Replidyne, Inc.

Replidyne is a biopharmaceutical company focused on discovering, developing, in-licensing and commercializing innovative anti-infective products. Replidyne's lead product, faropenem medoxomil, is a novel oral, community antibiotic, expected to be appropriate for use as a first-line antibiotic for treatment of respiratory and skin infections in adult and pediatric patients. Replidyne's second drug candidate, REP8839, is a topical anti-infective product candidate in development for the treatment of skin and wound infections, including methicillin-resistant S. aureus (MRSA) infections. Replidyne is also pursuing the development of other novel anti-infect
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Replidyne Phase II Pediatric Trial Meets Primary Objective
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:1/23/2015)...  Mallinckrodt plc (NYSE: MNK ) announced today ... repurchase program. The open-ended authorization permits the company to ... shares. "Funding additional initiatives and seeking ... continue to pursue a range of focused growth strategies," ...
(Date:1/22/2015)... 22, 2015  BiOptix is pleased to announce the appointment ... of Chemistry and Biochemistry. Scott joins the company after previous ... Amgen throughout the course of his nearly 20 year ... is a nationally recognized thought leader in the biosensor ...
(Date:1/22/2015)... 2015  Bio-Techne Corporation (NASDAQ: TECH ) announced ... of the new Simple Plex platform through its Proteins ... the re-branding of the previously acquired CyPlex instrument platform ... a transformative immunoassay technology which integrates an innovatively designed ...
Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3
... Sept. 15 VentiRx Pharmaceuticals, Inc., a biopharmaceutical company ... (TLR8) candidates for the treatment of cancer, respiratory and ... to the annual FierceBiotech "Fierce 15" list, designating it ... companies in the industry. Every year, FierceBiotech evaluates hundreds ...
... (Nasdaq: CYPB )  ("Cypress") today confirmed that Ramius ... all outstanding common shares of Cypress at a price of ... fiduciary duties and as required by applicable law, the Cypress ... course of action that it believes is in the best ...
Cached Medicine Technology:FierceBiotech Names VentiRx Pharmaceuticals as One of the 'Fierce 15' Biotech Companies of 2010 2Cypress Bioscience Board of Directors to Review Unsolicited Tender Offer from Ramius LLC 2
(Date:1/22/2015)... 2015 The City of West Hollywood hosted a ... commemorate the 42nd anniversary of the Supreme Court decision Roe v. ... 42 years since the Roe vs. Wade decision and the fight ... as ever,” said City of West Hollywood Councilmember Abbe Land. “We ...
(Date:1/22/2015)... Chemo Duck Program is pleased to announce the release of the ... with cancer. The Chemo Duck App, available on iTunes for use ... to help children of all ages living with cancer adjust to ... entertained, educated and at ease while waiting for clinic visits or ...
(Date:1/22/2015)... a seasoned and trusted leader who consistently delivers trendy dresses ... it lead the wedding dress industry into the future. Today, ... the global market. , “The CEO of VogueQueen is uniquely ... continuing the goal of operational excellence and giving back to ...
(Date:1/22/2015)... 23, 2015 Angelweddingdress is a famous wedding ... its customers to follow it on Facebook, Twitter, and Pinterest. ... Day gift. Angelweddingdress draws a lottery every week. , Moreover, ... Feb. 28, 2015. Click Angelweddingdress homepage for more ...
(Date:1/22/2015)... 2015 AngelWeddingDress, the premier women’s dress ... wedding dresses. View website of AngelWeddingDress.com to ... maternity wedding dresses online for a bridal party. AngelWeddingDress ... quality for them. Its maternity wedding dresses are specially ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2
... regional pain syndrome is a neurological disorder caused by continuous ... sense pain. // ,This syndrome includes all the post-traumatic ... injury has healed. But the causes of the symptoms of ... the fact that there are very few objective findings, diagnosis ...
... British Prime Minister Tony Blair today formally inducted 11 private ... further step towards increasing competition in the health sector. //Mr ... members at a summit held at Downing Street to mark ... signed a document pledging to work as partners towards 'future ...
... is the key to weight loss a new study says ... //, ,This study comes from the Canadian Institute for ... work can help make or break our battle against the ... CIHI's Canadian Population Health Initiative, "We see that the majority ...
... pollution in the air now that if it weren't for ... -Robert Orben // ,The order of the ... Clemenceau to be sent back to France, represents the overall ... The order has been issued following dismissal of the proposed ...
... profound impact on either couple, men seem to be more ... Christakis and his research team from Harvard Medical School. ... spouse on the risk of illness in the other partner ... elderly couples. ,They found that when a spouse ...
... at the Washington Hospital Center studied the use of ... blocked arteries. // ,These blocked arteries are ... as it leads to devastating complications such as amputation. ... high blood pressure are at high risk for losing ...
Cached Medicine News:Health News:Location largely affects weight 2Health News:The Return Of The Clemenceau: Happy India 2Health News:Laser Used To Clear Blocked Arteries Preventing Amputation, 2
... II Smart ValveTM, Hakim, H-V ... intelligent choice for meeting the ... Automatic pressure response causes the ... the conditions present, eliminating the ...
Codman Hakim Programmable valve cylindrical offers the ability to optimize the opening pressure of a shunt system before and after implantation. A shunted patient's condition will often change over t...
Leadpoint Micro-Electrode Recording...
... Using advanced 3D matching algorithms developed by ... automatically merges image sets from a variety ... PET, regardless of acquisition orientation. Stealthmerge even ... the requirement to scan tissue outside the ...
Medicine Products: